![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Ascentage Pharma
Ascentage Pharma is an integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs.
Investor Relations - Ascentage Pharma Group International
Ascentage Pharma Group International Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts.
About us - Ascentage Pharma
We are a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.
Ascentage Pharma was successfully listed on Nasdaq, becoming …
About Ascentage Pharma . Ascentage Pharma is a global biopharmaceutical company committed to developing innovative drugs to address unmet clinical needs in oncology and other therapeutic areas. On October 28, 2019, the Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code: 6855.HK.
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to …
Jan 24, 2025 · Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda holds an exclusive option to...
Ascentage Pharma raises $126m in first biotech IPO of 2025
Jan 24, 2025 · Ascentage sold 7,325,000 American Depositary shares at $17.25 each. Credit: Andrey Zhuravlev via Getty Images. China-based biotech Ascentage Pharma has raised $126m in a US initial public offering (IPO), marking the first biotech IPO of 2025. The company sold 7,325,000 American Depositary shares at ...
Ascentage Pharma Group Internat (AAPG) - Yahoo Finance
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
Jan 28, 2025 · Ascentage Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in...
Ascentage prices first biotech IPO of 2025, raising $126M
Jan 23, 2025 · Ascentage Pharma, a cancer drug developer based in Suzhou, China, on Thursday raised just over $126 million in the first U.S. initial public offering by a biotechnology company this year.
Takeda-backed Ascentage Pharma targets $1.8 bln valuation in …
Jan 21, 2025 · Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.
- Some results have been removed